A prevailing myth about preclinical research is that extensive studies delay launch and are too expensive. In fact, the opposite is true. Absorption, distribution, metabolism, and excretion (ADME) screenings have been shown to add value to a study, reduce risk, and strengthen the odds of achieving clinical approval. Finding a trusted partner to conduct and interpret ADME testing is a crucial step in the research pipeline. But what is the best entry point for a study? And what, if any, additional testing should be conducted during the process?

The following infographic by specialty global CRO, XenoTech, offers vital insights into the importance of ADME studies, including:

• When to perform ADME and other related studies
• Top four risks of delaying screenings 
• Steps sponsors can take to avoid clinical failures and mitigate risk